This systematic review provides a comprehensive overview of these mechanisms through which acquiring an IDH mutation and subsequent generalized DNA promoter methylation, affect various aspects of immune activation cycle in IDH‐mutant gliomas. This evidence concerns the gene IDH1 and central nervous system cancer.